First-line treatment of advanced ovarian cancer: current research and perspectives

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial

(2009) Maurie Markman et al.   GYNECOLOGIC ONCOLOGY

Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy

(2009) Jørn Herrstedt et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

(2009) Michael A. Bookman et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

(2009) Noriyuki Katsumata et al.   LANCET

Impact of vessel maturation on antiangiogenic therapy in ovarian cancer

(2008) Chunhua Lu et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Pharmaceutical Management of Ovarian Cancer

(2008) Maurie Markman   DRUGS

Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer

(2008) Chandra P. Belani et al.   JOURNAL OF CLINICAL ONCOLOGY

Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer

(2008) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial

(2008) S. Pignata et al.   ONCOLOGY